JP2002514171A - クラリスロマイシンの結晶形態iiの製造 - Google Patents
クラリスロマイシンの結晶形態iiの製造Info
- Publication number
- JP2002514171A JP2002514171A JP50903898A JP50903898A JP2002514171A JP 2002514171 A JP2002514171 A JP 2002514171A JP 50903898 A JP50903898 A JP 50903898A JP 50903898 A JP50903898 A JP 50903898A JP 2002514171 A JP2002514171 A JP 2002514171A
- Authority
- JP
- Japan
- Prior art keywords
- carbon atoms
- solvent
- water
- methylerythromycin
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 title claims abstract description 93
- 229960002626 clarithromycin Drugs 0.000 title claims abstract description 64
- 238000002360 preparation method Methods 0.000 title description 3
- 239000003960 organic solvent Substances 0.000 claims abstract description 19
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 claims abstract description 12
- 229960003276 erythromycin Drugs 0.000 claims abstract description 12
- 229930006677 Erythromycin A Natural products 0.000 claims abstract description 11
- 238000004519 manufacturing process Methods 0.000 claims abstract description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 66
- 125000004432 carbon atom Chemical group C* 0.000 claims description 63
- 239000002904 solvent Substances 0.000 claims description 57
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 40
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 32
- 238000000034 method Methods 0.000 claims description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 22
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 21
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 20
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 20
- 239000013078 crystal Substances 0.000 claims description 20
- 125000000217 alkyl group Chemical group 0.000 claims description 19
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 18
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical group C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 16
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical group CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 15
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 14
- 229930195733 hydrocarbon Natural products 0.000 claims description 13
- 150000002430 hydrocarbons Chemical class 0.000 claims description 13
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 claims description 12
- -1 carboxyl ester Chemical class 0.000 claims description 12
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims description 10
- 150000002576 ketones Chemical class 0.000 claims description 10
- 229910052739 hydrogen Inorganic materials 0.000 claims description 9
- 239000001257 hydrogen Substances 0.000 claims description 9
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 claims description 9
- 239000004215 Carbon black (E152) Substances 0.000 claims description 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 8
- 150000001555 benzenes Chemical group 0.000 claims description 8
- 150000001875 compounds Chemical class 0.000 claims description 8
- 229910052736 halogen Chemical group 0.000 claims description 8
- 150000002367 halogens Chemical group 0.000 claims description 8
- 229940011051 isopropyl acetate Drugs 0.000 claims description 8
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical group CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 claims description 8
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 8
- 125000003545 alkoxy group Chemical group 0.000 claims description 7
- FFOPEPMHKILNIT-UHFFFAOYSA-N butyric acid isopropyl ester Natural products CCCC(=O)OC(C)C FFOPEPMHKILNIT-UHFFFAOYSA-N 0.000 claims description 7
- 125000001424 substituent group Chemical group 0.000 claims description 7
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 6
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 claims description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 5
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical group CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 claims description 5
- 239000008096 xylene Substances 0.000 claims description 5
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical group CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 claims description 4
- 229940072049 amyl acetate Drugs 0.000 claims description 4
- PGMYKACGEOXYJE-UHFFFAOYSA-N anhydrous amyl acetate Natural products CCCCCOC(C)=O PGMYKACGEOXYJE-UHFFFAOYSA-N 0.000 claims description 4
- 150000002170 ethers Chemical class 0.000 claims description 4
- MNWFXJYAOYHMED-UHFFFAOYSA-M heptanoate Chemical compound CCCCCCC([O-])=O MNWFXJYAOYHMED-UHFFFAOYSA-M 0.000 claims description 4
- 239000003880 polar aprotic solvent Substances 0.000 claims description 4
- ZYBWTEQKHIADDQ-UHFFFAOYSA-N ethanol;methanol Chemical compound OC.CCO ZYBWTEQKHIADDQ-UHFFFAOYSA-N 0.000 claims description 3
- BCUMPULZWNQMKD-UHFFFAOYSA-N methanol;propan-2-yl acetate Chemical compound OC.CC(C)OC(C)=O BCUMPULZWNQMKD-UHFFFAOYSA-N 0.000 claims description 3
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims description 2
- BSCHIACBONPEOB-UHFFFAOYSA-N oxolane;hydrate Chemical compound O.C1CCOC1 BSCHIACBONPEOB-UHFFFAOYSA-N 0.000 claims description 2
- XTUSEBKMEQERQV-UHFFFAOYSA-N propan-2-ol;hydrate Chemical compound O.CC(C)O XTUSEBKMEQERQV-UHFFFAOYSA-N 0.000 claims description 2
- KYTWXIARANQMCA-RWJQBGPGSA-N (3r,4s,5s,6r,7r,9r,11s,12r,13s,14r)-6-[(2s,3r,4s,6r)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-7,12,13-trihydroxy-10-hydroxyimino-4-[(2r,4r,5s,6s)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,7,9,11,13-hexamethyl-oxacyclotetradecan-2 Chemical class O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=NO)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 KYTWXIARANQMCA-RWJQBGPGSA-N 0.000 claims 2
- ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 2,3-dimethylbutane Chemical group CC(C)C(C)C ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 0.000 claims 1
- 238000003763 carbonization Methods 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 239000012022 methylating agents Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 12
- 238000010992 reflux Methods 0.000 description 31
- 239000007787 solid Substances 0.000 description 30
- 239000000706 filtrate Substances 0.000 description 24
- 238000001953 recrystallisation Methods 0.000 description 20
- 239000000725 suspension Substances 0.000 description 15
- 238000001914 filtration Methods 0.000 description 12
- 239000005457 ice water Substances 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 7
- 238000007069 methylation reaction Methods 0.000 description 7
- 238000000634 powder X-ray diffraction Methods 0.000 description 7
- MWBJRTBANFUBOX-SQYJNGITSA-N (3r,4s,5s,6r,7r,9r,10e,11s,12r,13s,14r)-6-[(2s,3r,4s,6r)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-12,13-dihydroxy-10-hydroxyimino-4-[(2r,4r,5s,6s)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-7-methoxy-3,5,7,9,11,13-hexamethyl-oxacyclot Chemical group O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=N/O)/[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MWBJRTBANFUBOX-SQYJNGITSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical group CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 230000011987 methylation Effects 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 125000006239 protecting group Chemical group 0.000 description 6
- 238000001757 thermogravimetry curve Methods 0.000 description 5
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 4
- 238000010511 deprotection reaction Methods 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 238000003386 deoximation reaction Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000002329 infrared spectrum Methods 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 150000002923 oximes Chemical class 0.000 description 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 3
- 239000011877 solvent mixture Substances 0.000 description 3
- SPEUIVXLLWOEMJ-UHFFFAOYSA-N 1,1-dimethoxyethane Chemical compound COC(C)OC SPEUIVXLLWOEMJ-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 235000010650 Hyssopus officinalis Nutrition 0.000 description 2
- 240000001812 Hyssopus officinalis Species 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- 238000002441 X-ray diffraction Methods 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 229940100198 alkylating agent Drugs 0.000 description 2
- 239000002168 alkylating agent Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000000113 differential scanning calorimetry Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- XNLICIUVMPYHGG-UHFFFAOYSA-N methyl n-propyl ketone Natural products CCCC(C)=O XNLICIUVMPYHGG-UHFFFAOYSA-N 0.000 description 2
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 2
- FDPIMTJIUBPUKL-UHFFFAOYSA-N pentan-3-one Chemical compound CCC(=O)CC FDPIMTJIUBPUKL-UHFFFAOYSA-N 0.000 description 2
- 238000006485 reductive methylation reaction Methods 0.000 description 2
- 239000013557 residual solvent Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- LZDKZFUFMNSQCJ-UHFFFAOYSA-N 1,2-diethoxyethane Chemical compound CCOCCOCC LZDKZFUFMNSQCJ-UHFFFAOYSA-N 0.000 description 1
- QWUWMCYKGHVNAV-UHFFFAOYSA-N 1,2-dihydrostilbene Chemical group C=1C=CC=CC=1CCC1=CC=CC=C1 QWUWMCYKGHVNAV-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- NAMDIHYPBYVYAP-UHFFFAOYSA-N 1-methoxy-2-(2-methoxyethoxy)ethane Chemical compound COCCOCCOC.COCCOCCOC NAMDIHYPBYVYAP-UHFFFAOYSA-N 0.000 description 1
- ZYVYEJXMYBUCMN-UHFFFAOYSA-N 1-methoxy-2-methylpropane Chemical compound COCC(C)C ZYVYEJXMYBUCMN-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- UZFMOKQJFYMBGY-UHFFFAOYSA-N 4-hydroxy-TEMPO Chemical compound CC1(C)CC(O)CC(C)(C)N1[O] UZFMOKQJFYMBGY-UHFFFAOYSA-N 0.000 description 1
- ZYUVGYBAPZYKSA-UHFFFAOYSA-N 5-(3-hydroxybutan-2-yl)-4-methylbenzene-1,3-diol Chemical compound CC(O)C(C)C1=CC(O)=CC(O)=C1C ZYUVGYBAPZYKSA-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Chemical group IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
- YSVZGWAJIHWNQK-UHFFFAOYSA-N [3-(hydroxymethyl)-2-bicyclo[2.2.1]heptanyl]methanol Chemical compound C1CC2C(CO)C(CO)C1C2 YSVZGWAJIHWNQK-UHFFFAOYSA-N 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 229940087430 biaxin Drugs 0.000 description 1
- GZUXJHMPEANEGY-BJUDXGSMSA-N bromomethane Chemical group Br[11CH3] GZUXJHMPEANEGY-BJUDXGSMSA-N 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- NHADDZMCASKINP-HTRCEHHLSA-N decarboxydihydrocitrinin Natural products C1=C(O)C(C)=C2[C@H](C)[C@@H](C)OCC2=C1O NHADDZMCASKINP-HTRCEHHLSA-N 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000006392 deoxygenation reaction Methods 0.000 description 1
- 125000005265 dialkylamine group Chemical group 0.000 description 1
- 235000013367 dietary fats Nutrition 0.000 description 1
- POLCUAVZOMRGSN-UHFFFAOYSA-N dipropyl ether Chemical compound CCCOCCC POLCUAVZOMRGSN-UHFFFAOYSA-N 0.000 description 1
- UZZWBUYVTBPQIV-UHFFFAOYSA-N dme dimethoxyethane Chemical compound COCCOC.COCCOC UZZWBUYVTBPQIV-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 235000019256 formaldehyde Nutrition 0.000 description 1
- 229960004279 formaldehyde Drugs 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000010520 ghee Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000012943 hotmelt Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 150000002443 hydroxylamines Chemical class 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical group IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- GJRQTCIYDGXPES-UHFFFAOYSA-N iso-butyl acetate Natural products CC(C)COC(C)=O GJRQTCIYDGXPES-UHFFFAOYSA-N 0.000 description 1
- FGKJLKRYENPLQH-UHFFFAOYSA-M isocaproate Chemical compound CC(C)CCC([O-])=O FGKJLKRYENPLQH-UHFFFAOYSA-M 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- OQAGVSWESNCJJT-UHFFFAOYSA-N isovaleric acid methyl ester Natural products COC(=O)CC(C)C OQAGVSWESNCJJT-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 1
- 238000006146 oximation reaction Methods 0.000 description 1
- 125000005429 oxyalkyl group Chemical group 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
- C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1. 6−O−メチルエリスロマイシンA結晶形態IIの製造方法であって、該 製造方法が、 (a) エリスロマイシンAを6−O−メチルエリスロマイシンAに変換し; (b) 段階dにおいて製造された6−O−メチルエリスロマイシンAを、 (i)炭素原子1〜5個のアルカノール、但し、該アルカノールがエタノー ルまたはイソプロパノールではないことを条件とする、 (ii)炭素原子5〜12個の炭化水素、 (iii)炭素原子3〜12個のケトン、 (iv)炭素原子3〜12個のカルボキシルエステル、但し、該カルボキシ ルエステルが酢酸イソプロピルではないことを条件とする、 (v)炭素原子4〜10個のエーテル、 (vi)ベンゼン、 (vii)炭素原子1〜4個のアルキル、 炭素原子1〜4個のアルコキシ、 ニトロ、および ハロゲン、 から成る群から選択される1つまたはそれ以上の置換基で置換されたベンゼン、 (viii)極性非プロトン性溶媒、 (ix)式HNR1R2[式中、R1およびR2はそれぞれ、水素および炭素原 子1〜4個のアルキルから選択され、但し、R1およびR2の両方が水素でないこ とを条件とする。]で示される化合物、 (x)水、ならびに 水混和性有機溶媒、および 水混和性アルカノール、 から成る群から選択される水混和性溶媒、 (xi)メタノール、ならびに 炭素原子5〜12個の炭化水素、 炭素原子2〜5個のアルカノール、 炭素原子3〜12個のケトン、 炭素原子3〜12個のカルボキシルエステル、 炭素原子4〜10個のエーテル、 ベンゼン、および 炭素原子1〜4個のアルキル、 炭素原子1〜4個のアルコキシ、 ニトロ、および ハロゲン、 から成る群から選択される1つまたはそれ以上の置換基で置換されたベ ンゼン、 から成る群から選択される第二溶媒、および (xii)炭素原子5〜12個の炭化水素、ならびに 炭素原子3〜12個のケトン、 炭素原子3〜12個のカルボキシルエステル、 炭素原子4〜10個のエーテル、 ベンゼン、 炭素原子1〜4個のアルキル、 炭素原子1〜4個のアルコキシ、 ニトロ、および ハロゲン、 から成る群から選択される1つまたはそれ以上の置換 基で置換されたベンゼン、および 極性非プロトン溶媒、 から成る群から選択される第二溶媒、 から成る群から選択される溶媒で処理し;および (f) 6−O−メチルエリスロマイシンA形態II結晶を単離する; ことを含んで成る方法。 2. 工程(a)が、 (i) エリスロマイシンAをエリスロマイシンA9−オキシム誘導体に変換 し; (ii) 工程(i)で製造されるエリスロマイシンA9−オキシム誘導体の 2’および4”ヒドロキシ基を保護し; (iii) 工程(ii)の生成物をメチル化剤と反応させ; (iv) 工程(iii)の生成物を脱保護および脱オキシムして、6−O−メ チルエリスロマイシンAを生成する; ことを含んで成る請求項1に記載の方法。 3. 溶媒が、水、および水混和性有機溶媒または水混和性アルカノールを含ん で成る請求項2に記載の方法。 4. 溶媒が、水、および水混和性有機溶媒または水混和性ア ルカノールを、約1:1容量部の比率で含んで成る請求項3に記載の方法。 5. 溶媒が、水および水混和性有機溶媒を含んで成る請求項4に記載の方法。 6. 水混和性有機溶媒がテトラヒドロフランである請求項5に記載の6−O− メチルエリスロマイシンA結晶形態IIの製造方法。 7. 溶媒が、水および水混和性アルカノールを含んで成る請求項4に記載の方 法。 8. 水混和性アルカノールが、メタノール、エタノールおよびイソプロパノー ルから成る群から選択される請求項7に記載の方法。 9. 溶媒が、メタノール、ならびに 炭素原子5〜12個の炭化水素、 炭素原子2〜5個のアルカノール、 炭素原子3〜12個のケトン、 炭素原子3〜12個のカルボキシルエステル、 炭素原子4〜10個のエーテル、 ベンゼン、および 炭素原子1〜4個のアルキル、 炭素原子1〜4個のアルコキシ、 ニトロ、および ハロゲン、 から成る群から選択される1つまたはそれ以上の置換基で置換されたベンゼン 、 から成る群から選択される第二溶媒、を含んで成る請求項2に記載の方法。 10. 溶媒が、メタノール、ならびに 炭素原子2〜5個のアルカノール、または 炭素原子3〜12個のカルボキシルエステル、 を含んで成る請求項9に記載の方法。 11. 溶媒が、メタノール、ならびに炭素原子2〜5個のアルカノールまたは 炭素原子3〜12個のカルボキシルエステルを、約1:1容量部の比率で含んで 成る請求項10に記載の方法。 12. 溶媒が、メタノール、ならびにエタノールおよび酢酸イソプロピルから 成る群から選択される第二溶媒を含んで成る請求項11に記載の方法。 13. 溶媒が、式HNR1R2[式中、R1およびR2はそれぞれ、水素および炭 素原子1〜4個のアルキルから選択され、但し、R1およびR2の両方が水素でな いことを条件とする。]で示される化合物を含んで成る請求項2に記載の方法。 14. 溶媒がイソプロピルアミンである請求項13に記載の方法。 15. 溶媒が、 アセトン、 ヘプタン、 トルエン、 メチルtert−ブチルエーテル、 N,N−ジメチルホルムアミド、 酢酸エチル、 キシレン、 イソプロパノール−水、 テトラヒドロフラン−水、 エタノール−水、 エチルエーテル、 酢酸アミル、 酢酸イソプロピル−メタノール、 ジイソプロピルエーテル、 酪酸イソプロピル、 イソプロピルアミン、および メタノール−エタノール、 から成る群から選択される請求項2に記載の方法。 16.請求項2に記載の方法によって製造される6−O−メチルエリスロマイシ ンA形態II。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/681,695 | 1996-07-29 | ||
US08/681,695 US5844105A (en) | 1996-07-29 | 1996-07-29 | Preparation of crystal form II of clarithromycin |
US90027197A | 1997-07-25 | 1997-07-25 | |
US08/900,271 | 1997-07-25 | ||
PCT/US1997/013166 WO1998004574A1 (en) | 1996-07-29 | 1997-07-28 | Preparation of crystal form ii of clarithromycin |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2005357782A Division JP2006137765A (ja) | 1996-07-29 | 2005-12-12 | クラリスロマイシンの結晶形態iiの製造 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2002514171A true JP2002514171A (ja) | 2002-05-14 |
JP2002514171A5 JP2002514171A5 (ja) | 2005-02-10 |
JP4104660B2 JP4104660B2 (ja) | 2008-06-18 |
Family
ID=27102712
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP50903898A Expired - Lifetime JP4104660B2 (ja) | 1996-07-29 | 1997-07-28 | クラリスロマイシンの結晶形態iiの製造 |
JP2005357782A Pending JP2006137765A (ja) | 1996-07-29 | 2005-12-12 | クラリスロマイシンの結晶形態iiの製造 |
JP2009141790A Withdrawn JP2009242411A (ja) | 1996-07-29 | 2009-06-15 | クラリスロマイシンの結晶形態iiの製造 |
JP2013077418A Pending JP2013151542A (ja) | 1996-07-29 | 2013-04-03 | クラリスロマイシンの結晶形態iiの製造 |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2005357782A Pending JP2006137765A (ja) | 1996-07-29 | 2005-12-12 | クラリスロマイシンの結晶形態iiの製造 |
JP2009141790A Withdrawn JP2009242411A (ja) | 1996-07-29 | 2009-06-15 | クラリスロマイシンの結晶形態iiの製造 |
JP2013077418A Pending JP2013151542A (ja) | 1996-07-29 | 2013-04-03 | クラリスロマイシンの結晶形態iiの製造 |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP0915899B1 (ja) |
JP (4) | JP4104660B2 (ja) |
KR (1) | KR100524214B1 (ja) |
AT (1) | ATE272646T1 (ja) |
AU (1) | AU733646B2 (ja) |
CA (1) | CA2261732C (ja) |
DE (3) | DE97934319T1 (ja) |
DK (1) | DK0915899T3 (ja) |
ES (1) | ES2173057T3 (ja) |
IL (1) | IL127833A (ja) |
PT (1) | PT915899E (ja) |
WO (1) | WO1998004574A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007326880A (ja) * | 2004-02-20 | 2007-12-20 | Enanta Pharmaceuticals Inc | 6−11二環式ケトライド誘導体の多型形態 |
JP2012107075A (ja) * | 2006-12-05 | 2012-06-07 | Bristol Myers Squibb Co | モチライド類の多型 |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5945405A (en) * | 1997-01-17 | 1999-08-31 | Abbott Laboratories | Crystal form O of clarithromycin |
CA2245398C (en) | 1998-08-21 | 2002-01-29 | Apotex Inc. | Azithromycin monohydrate isopropanol clathrate and methods for the manufacture thereof |
KR100377159B1 (ko) * | 1998-09-09 | 2003-08-19 | 한미약품공업 주식회사 | 잔류 용매가 없는 클라리스로마이신의 결정형 2의 제조 방법 |
GB9827355D0 (en) | 1998-12-11 | 1999-02-03 | Biochemie Sa | Organic compounds |
KR20010008496A (ko) * | 1999-07-01 | 2001-02-05 | 유충식 | 6-오-메틸 에리트로마이신의 제조방법 |
KR100322313B1 (ko) * | 1999-10-21 | 2002-02-06 | 민경윤 | 클라리스로마이신 결정형 2의 제조방법 및 이에 사용되는 클라리스로마이신 포르메이트 |
US6627743B1 (en) | 1999-12-03 | 2003-09-30 | Abbott Laboratories | 6-O-methylerythromycin A crystal form III |
KR20020070991A (ko) | 1999-12-16 | 2002-09-11 | 테바 파마슈티컬 인더스트리즈 리미티드 | 클라리트로마이신 다형체 및 신규의 다형체 ⅳ의 제조 방법 |
HUP0204252A3 (en) | 2000-01-11 | 2003-04-28 | Teva Pharma | Process for preparing clarithromycin polymorphs and pharmaceutical compositions containing them |
WO2001064224A1 (en) | 2000-02-29 | 2001-09-07 | Teva Pharmaceutical Industries Ltd. | Processes for preparing clarithromycin and clarithromycin intermediate, essentially oxime-free clarithromycin, and pharmaceutical composition comprising the same |
KR100361397B1 (ko) * | 2000-03-15 | 2002-11-23 | 한미약품공업 주식회사 | 에리스로마이신 에이 9-오-트로필옥심 유도체를 이용한클라리스로마이신의 제조방법 |
MXPA02008861A (es) * | 2000-03-15 | 2003-02-10 | Hanmi Pharm Ind Co Ltd | Metodo para preparar claritromicina de cristales de forma ii. |
KR100367981B1 (ko) * | 2000-11-23 | 2003-01-14 | 한미약품공업 주식회사 | 클라리스로마이신 결정형 2의 제조 방법 및 이 방법에사용되는 결정성 클라리스로마이신 메실레이트 삼수화물 |
KR100408848B1 (ko) * | 2001-03-12 | 2003-12-06 | 주식회사 씨트리 | 클래리스로마이신의 정제방법 |
SI1390377T1 (sl) * | 2001-05-22 | 2006-06-30 | Pfizer Prod Inc | Nova kristalna oblika azitromicina |
JP2004530703A (ja) * | 2001-05-22 | 2004-10-07 | ファイザー・プロダクツ・インク | 結晶形アジスロマイシン |
US6861413B2 (en) | 2001-05-22 | 2005-03-01 | Pfizer Inc. | Stable non-dihydrate azithromycin oral suspensions |
KR100372254B1 (en) * | 2002-07-15 | 2003-02-19 | Korea United Pharm Inc | Erythromycin a 9-o-pseudosaccharinyl oxime derivative and process for preparing clarithromycin using the same |
EP1435359A1 (en) * | 2002-12-31 | 2004-07-07 | Alembic Limited | A process for the purification of roxithromycin |
DE102007016367A1 (de) * | 2007-04-03 | 2008-10-09 | Grünenthal GmbH | Polymorph von Clarithromycin (Form V) |
CN103087130B (zh) * | 2013-02-06 | 2015-12-23 | 浙江国邦药业有限公司 | 一种克拉霉素晶型转换方法 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5782400A (en) | 1980-11-12 | 1982-05-22 | Taisho Pharmaceut Co Ltd | Erythromycin derivative |
JPS572298A (en) * | 1980-06-04 | 1982-01-07 | Taisho Pharmaceut Co Ltd | Erythromycin derivative |
US4331803A (en) | 1980-06-04 | 1982-05-25 | Taisho Pharmaceutical Co., Ltd. | Novel erythromycin compounds |
JPS60214796A (ja) * | 1984-04-06 | 1985-10-28 | Taisho Pharmaceut Co Ltd | 6−0−メチルエリスロマイシン類の製法 |
JPS61103890A (ja) | 1984-10-26 | 1986-05-22 | Taisho Pharmaceut Co Ltd | 6−0−メチルエリスロマイシンa誘導体 |
US4670549A (en) * | 1985-03-18 | 1987-06-02 | Taisho Pharmaceutical Co., Ltd. | Method for selective methylation of erythromycin a derivatives |
DE3782994T2 (de) | 1986-09-18 | 1993-04-08 | Taisho Pharma Co Ltd | Erythromycin-a-derivate und verfahren zu ihrer herstellung. |
JPH0755958B2 (ja) * | 1986-10-03 | 1995-06-14 | 大正製薬株式会社 | エリスロマイシンa誘導体の製造方法 |
JP2526951B2 (ja) * | 1986-12-17 | 1996-08-21 | 大正製薬株式会社 | エリスロマイシンa誘導体およびその製造方法 |
KR960000434B1 (ko) * | 1986-12-17 | 1996-01-06 | 다이쇼 세이야꾸 가부시끼가이샤 | 에리스로마이신 a유도체 및 그의 제조 방법 |
JP2782793B2 (ja) * | 1988-06-15 | 1998-08-06 | 大正製薬株式会社 | エリスロマイシンa誘導体およびその製造方法 |
ZA922777B (en) * | 1991-04-29 | 1993-10-15 | Lilly Co Eli | Pharmaceutical formulation containing dirithromycin |
US5872229A (en) | 1995-11-21 | 1999-02-16 | Abbott Laboratories | Process for 6-O-alkylation of erythromycin derivatives |
US5837829A (en) | 1996-04-02 | 1998-11-17 | Abbott Laboratories | 9-oximesilyl erythromycin a derivatives |
US5719272A (en) | 1996-04-02 | 1998-02-17 | Abbott Laboratories | 2'-protected 3'-dimethylamine, 9-etheroxime erythromycin A derivatives |
-
1997
- 1997-07-28 EP EP97934319A patent/EP0915899B1/en not_active Revoked
- 1997-07-28 DK DK97934319T patent/DK0915899T3/da active
- 1997-07-28 AU AU37405/97A patent/AU733646B2/en not_active Expired
- 1997-07-28 DE DE0000915899T patent/DE97934319T1/de active Pending
- 1997-07-28 KR KR10-1999-7000654A patent/KR100524214B1/ko not_active IP Right Cessation
- 1997-07-28 DE DE29724846U patent/DE29724846U1/de not_active Expired - Lifetime
- 1997-07-28 PT PT97934319T patent/PT915899E/pt unknown
- 1997-07-28 DE DE69730138T patent/DE69730138T2/de not_active Revoked
- 1997-07-28 JP JP50903898A patent/JP4104660B2/ja not_active Expired - Lifetime
- 1997-07-28 AT AT97934319T patent/ATE272646T1/de active
- 1997-07-28 ES ES97934319T patent/ES2173057T3/es not_active Expired - Lifetime
- 1997-07-28 IL IL12783397A patent/IL127833A/en not_active IP Right Cessation
- 1997-07-28 WO PCT/US1997/013166 patent/WO1998004574A1/en not_active Application Discontinuation
- 1997-07-28 CA CA002261732A patent/CA2261732C/en not_active Expired - Lifetime
-
2005
- 2005-12-12 JP JP2005357782A patent/JP2006137765A/ja active Pending
-
2009
- 2009-06-15 JP JP2009141790A patent/JP2009242411A/ja not_active Withdrawn
-
2013
- 2013-04-03 JP JP2013077418A patent/JP2013151542A/ja active Pending
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007326880A (ja) * | 2004-02-20 | 2007-12-20 | Enanta Pharmaceuticals Inc | 6−11二環式ケトライド誘導体の多型形態 |
JP2012107075A (ja) * | 2006-12-05 | 2012-06-07 | Bristol Myers Squibb Co | モチライド類の多型 |
Also Published As
Publication number | Publication date |
---|---|
ES2173057T1 (es) | 2002-10-16 |
JP2013151542A (ja) | 2013-08-08 |
AU733646B2 (en) | 2001-05-17 |
IL127833A (en) | 2004-06-20 |
KR20000029591A (ko) | 2000-05-25 |
EP0915899A1 (en) | 1999-05-19 |
JP2006137765A (ja) | 2006-06-01 |
JP4104660B2 (ja) | 2008-06-18 |
CA2261732C (en) | 2001-07-24 |
KR100524214B1 (ko) | 2005-11-01 |
JP2009242411A (ja) | 2009-10-22 |
ES2173057T3 (es) | 2004-11-16 |
DE29724846U1 (de) | 2004-12-16 |
IL127833A0 (en) | 1999-10-28 |
DK0915899T3 (da) | 2004-11-29 |
EP0915899B1 (en) | 2004-08-04 |
WO1998004574A1 (en) | 1998-02-05 |
DE97934319T1 (de) | 2004-08-26 |
PT915899E (pt) | 2004-11-30 |
DE69730138T2 (de) | 2005-03-03 |
DE69730138D1 (de) | 2004-09-30 |
ATE272646T1 (de) | 2004-08-15 |
AU3740597A (en) | 1998-02-20 |
CA2261732A1 (en) | 1998-02-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2002514171A (ja) | クラリスロマイシンの結晶形態iiの製造 | |
US5844105A (en) | Preparation of crystal form II of clarithromycin | |
JP5290136B2 (ja) | クラリスロマイシンの結晶フォームi | |
RU2230748C2 (ru) | Способ получения кларитромицина в виде кристаллов формы ii | |
EP0180415B1 (en) | A 6-0-methylerythromycin A derivative | |
EP1280535B1 (en) | Processes for preparing clarithromycin polymorphs | |
KR100322313B1 (ko) | 클라리스로마이신 결정형 2의 제조방법 및 이에 사용되는 클라리스로마이신 포르메이트 | |
CA2393047A1 (en) | 6-o-methylerythromycin a crystal form iii | |
WO2009053259A1 (en) | Process for the production of telithromycin | |
CA2067274C (en) | Solvates of dirithromycin and a process for isolating form ii dirithromycin | |
KR100467707B1 (ko) | 클래리트로마이신의 제 2결정형의 제조 방법 | |
CA2386527C (en) | Crystal form i of clarithromycin | |
CA2526732A1 (en) | Q-alkyl macrolide and azalide derivatives and regioselective process for their preparation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040407 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040407 |
|
A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20040407 |
|
A975 | Report on accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A971005 Effective date: 20040716 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20040907 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20041206 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20050124 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050304 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20050816 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20051209 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060111 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20060202 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20060518 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080220 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20080326 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110404 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130404 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140404 Year of fee payment: 6 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |